JeffreyÂ N Weitzel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/820081/publications.pdf

Version: 2024-02-01

137	13,396	34105	24258
papers	citations	52 h-index	110 g-index

143	143	143	15232
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	7.4	1,241
2	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
3	Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. Journal of Clinical Oncology, 2009, 27, 1250-1256.	1.6	532
4	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	4.9	498
5	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
6	Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 2021, 124, 315-332.	6.4	447
7	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	27.0	414
8	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	4.9	408
9	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
10	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
11	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
12	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
13	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
14	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
15	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	6.2	257
16	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
17	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
18	RAD51 135Gâ†’C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217

#	Article	IF	Citations
19	Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Science Translational Medicine, 2019, 11, .	12.4	197
20	Genetics, genomics, and cancer risk assessment. Ca-A Cancer Journal for Clinicians, 2011, 61, 327-359.	329.8	172
21	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
22	Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2587.	7.4	164
23	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	160
24	Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1666-1671.	2.5	157
25	Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis. Archives of Surgery (Chicago, Ill: 1920), 2003, 138, 1323.	1.4	155
26	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
27	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 2012, 133, 1125-1130.	2.5	144
28	Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. Journal of Clinical Oncology, 2013, 31, 210-216.	1.6	140
29	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
30	Circulating tumor DNA as an early cancer detection tool. , 2020, 207, 107458.		123
31	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
32	Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Frontiers in Oncology, 2015, 5, 208.	2.8	109
33	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	5.2	108
34	Validity of Models for Predicting BRCA1 and BRCA2 Mutations. Annals of Internal Medicine, 2007, 147, 441.	3.9	106
35	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	3.5	105
36	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	6.4	101

#	Article	IF	Citations
37	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
38	Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1615-1620.	2.5	92
39	Somatic TP53 variants frequently confound germ-line testing results. Genetics in Medicine, 2018, 20, 809-816.	2.4	91
40	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
41	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
42	Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome. Molecular Diagnosis and Therapy, 2013, 17, 31-47.	3.8	82
43	Comprehensive spectrum ofBRCA1andBRCA2deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics, 2016, 53, 15-23.	3.2	82
44	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
45	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	1.6	79
46	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Network Open, 2020, 3, e208501.	5.9	79
47	Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer, 2015, 121, 372-378.	4.1	78
48	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
49	Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. Genetics in Medicine, 2014, 16, 588-593.	2.4	62
50	BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecologic Oncology, 2012, 124, 236-243.	1.4	60
51	If We Build Itâ€‰â€¦Will They Come? â€“ Establishing a Cancer Genetics Services Clinic for an Underserved Predominantly Latina Cohort. Journal of Genetic Counseling, 2006, 15, 505-514.	1.6	59
52	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
53	Factors influencing ovulation and the risk of ovarian cancer in <scp>BRCA1</scp> and <scp>BRCA2</scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	5.1	56
54	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800.	7.1	55

#	Article	IF	Citations
55	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
56	A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women. Journal of the National Cancer Institute, 2020, 112, 590-598.	6.3	53
57	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
58	Li-Fraumeni syndrome: not a straightforward diagnosis anymoreâ€"the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 2019, 21, 107.	5.0	51
59	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2020, 112, 1213-1221.	6.3	51
60	Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry. Journal of the National Cancer Institute, 2018, 110, 1059-1066.	6.3	48
61	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
62	Genetic cancer risk assessment. Cancer, 1999, 86, 2483-2492.	4.1	47
63	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
64	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. Journal of Clinical Oncology, 2021, 39, 2564-2573.	1.6	47
65	Socialâ€cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psycho-Oncology, 2008, 17, 774-782.	2.3	45
66	Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The Power of Partnership. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 615-624.	4.9	45
67	A Comparison of Bilateral Breast Cancers in BRCA Carriers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1534-1538.	2.5	44
68	Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCAâ€negative Hispanics with breast cancer. Cancer, 2019, 125, 2829-2836.	4.1	43
69	Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce. Genetics in Medicine, 2011, 13, 832-840.	2.4	42
70	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from MedellÃn, Colombia. Hereditary Cancer in Clinical Practice, 2014, 12, 11.	1.5	42
71	Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. Genetic Testing and Molecular Biomarkers, 2015, 19, 657-665.	0.7	42
72	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42

#	Article	IF	Citations
73	Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research Network. Cancer Genetics, 2017, 216-217, 111-119.	0.4	42
74	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	9.4	41
75	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precision Oncology, 2020, 4, 585-592.	3.0	41
76	The effects of genomic germline variant reclassification on clinical cancer care. Oncotarget, 2019, 10, 417-423.	1.8	40
77	Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. Journal of Community Genetics, 2016, 7, 177-183.	1.2	39
78	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
79	Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonistâ€“Based Chemoprevention Regimen in BRCA1 Carriers. Clinical Cancer Research, 2007, 13, 654-658.	7.0	36
80	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 268-276.	2.0	36
81	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
82	Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genetics, 2016, 209, 417-422.	0.4	33
83	Beliefs and interest in cancer risk in an underserved Latino cohort. Preventive Medicine, 2007, 44, 241-245.	3.4	32
84	Identification of novel common breast cancer risk variants at the 6q25 locusÂamong Latinas. Breast Cancer Research, 2019, 21, 3.	5.0	32
85	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.9	32
86	Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genetics in Medicine, 2005, 7, 40-47.	2.4	31
87	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
88	Genetics of gastric cancer: what do we know about the genetic risks?. Translational Gastroenterology and Hepatology, 2019, 4, 55-55.	3.0	30
89	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
90	The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Familial Cancer, 2018, 17, 235-245.	1.9	29

#	Article	IF	Citations
91	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
92	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
93	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genetics, 2019, 235-236, 31-38.	0.4	23
94	Genetic cancer risk assessment. Cancer, 1999, 86, 2483-2492.	4.1	23
95	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
96	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	1.6	22
97	Evolving perspectives on genetic discrimination in health insurance among health care providers. Familial Cancer, 2010, 9, 253-260.	1.9	21
98	Impact of Web-Based Case Conferencing on Cancer Genetics Training Outcomes for Community-Based Clinicians. Journal of Cancer Education, 2012, 27, 217-225.	1.3	21
99	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Journal of Clinical Oncology, 2021, 39, 3430-3440.	1.6	21
100	Absence of the BRCA1 del (exons 9â€“12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Research and Treatment, 2009, 117, 679-681.	2.5	19
101	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2517-2521.	2.0	19
102	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
103	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
104	Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Research and Treatment, 2011, 130, 281-289.	2.5	17
105	Germline mutations and age at onset of lung adenocarcinoma. Cancer, 2021, 127, 2801-2806.	4.1	14
106	Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1179-1184.	2.4	13
107	Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. Npj Breast Cancer, 2021, 7, 107.	5.2	13
108	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment, 2016, 160, 121-129.	2.5	11

#	Article	IF	Citations
109	The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients. Journal of the American Geriatrics Society, 2019, 67, 884-888.	2.6	11
110	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
111	Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer. JAMA Oncology, 2016, 2, 723.	7.1	10
112	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	2.5	10
113	Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer, 2020, 20, 1053.	2.6	10
114	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	3.0	9
115	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. JCO Precision Oncology, 2021, 5, 1073-1081.	3.0	9
116	Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis. Journal of Geriatric Oncology, 2020, 11, 316-319.	1.0	8
117	Breast cancer associated pathogenic variants among women 61â€¯years and older with triple negative breast cancer. Journal of Geriatric Oncology, 2021, 12, 749-751.	1.0	8
118	Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis ofBRCA1 exon 11 mutations in a high-risk breast cancer cohort. Human Mutation, 2002, 19, 656-663.	2.5	7
119	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	2.5	7
120	Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	3.0	7
121	Linkage of a Pedigree Drawing Program and Database to a Program for Determining BRCA Mutation Carrier Probability. Familial Cancer, 2005, 4, 313-316.	1.9	6
122	Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico. JCO Global Oncology, 2021, 7, 992-1002.	1.8	6
123	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	2.5	6
124	The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas. Current Opinion in Obstetrics and Gynecology, 1999, 11, 65-70.	2.0	6
125	The Genetics of Breast Cancer. Surgical Oncology Clinics of North America, 2015, 24, 705-732.	1.5	5
126	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5

#	Article	IF	Citations
127	Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome. Cancer Genetics, 2017, 212-213, 1-7.	0.4	4
128	Genetic cancer predisposition syndromes among older adults. Journal of Geriatric Oncology, 2020, 11, 1054-1060.	1.0	4
129	Multigene assessment of genetic risk for women for two or more breast cancers. Breast Cancer Research and Treatment, 2021, 188, 759-768.	2.5	4
130	Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity. Genetics in Medicine, 2022, 24, 673-680.	2.4	4
131	Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. Journal of Cancer Education, 2019, 34, 1204-1212.	1.3	3
132	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1621-1629.	2.5	2
133	The crystal ball of genetic cancer risk assessment: Who wouldn't want to know their future?. Annals of Surgical Oncology, 1998, 5, 567-568.	1.5	1
134	Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer. Cancer Research Communications, 2021, 1, 140-147.	1.7	1
135	Reply to J. Tinat et al. Journal of Clinical Oncology, 2009, 27, e110-e110.	1.6	0
136	Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer. Salud Publica De Mexico, 2022, 64, 41-48.	0.4	0
137	Crossâ€sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment. Journal of Genetic Counseling, 0, , .	1.6	0